Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Other financing activities (2022 - 2025)

Core Laboratories filings provide 4 years of Other financing activities readings, the most recent being -$254000.0 for Q4 2025.

  • On a quarterly basis, Other financing activities fell 106.76% to -$254000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was $1.6 million, a 77.95% decrease, with the full-year FY2025 number at -$254000.0, down 106.76% from a year prior.
  • Other financing activities hit -$254000.0 in Q4 2025 for Core Laboratories, down from $1.3 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $12.7 million in Q4 2023 to a low of -$7.0 million in Q4 2022.
  • Median Other financing activities over the past 4 years was $1.3 million (2025), compared with a mean of $1.6 million.
  • The widest YoY moves for Other financing activities: up 2519.57% in 2024, down 122.96% in 2024.
  • Core Laboratories' Other financing activities stood at -$7.0 million in 2022, then surged by 280.66% to $12.7 million in 2023, then crashed by 70.48% to $3.8 million in 2024, then plummeted by 106.76% to -$254000.0 in 2025.
  • The last three reported values for Other financing activities were -$254000.0 (Q4 2025), $1.3 million (Q3 2025), and $539000.0 (Q2 2025) per Business Quant data.